Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment

Hepatobiliary and Pancreatic Diseases International

Volumn 5, Issue 3, 2006, Pages 374-380

  Sarin, Shiv K ^a   Kumar, Manoj ^a   Hissar, Syed ^a   Sharma, Barjesh C ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Chronic hepatitis B; Lamivudine; Non responder; Pegylated interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA INTERFERON; AMYLASE; CREATINE KINASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B; VIRUS DNA;

ABDOMINAL DISCOMFORT; ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER TOXICITY; MALAISE; MALE; NAUSEA; SCORING SYSTEM; SEROCONVERSION; THROMBOCYTE DYSFUNCTION; TREATMENT FAILURE; VOMITING;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOPSY; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33748073756     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-2094.
2. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.
3. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
4. Marcellin P, Chang TT, Lim SG, Tony MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the reatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
5. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B: an Italian multicenter, randomized trial. J Hepatol 2001;35:406-411.
6. Carreno V, Marcellin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant-interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP) Hepatology 1999;30:277-282.
7. Munoz R, Castellano G, Fernandez I, Alvarez MV, Manzano ML, Marcos MS, et al. A pilot study of b-interferon for treatment of patients with chronic hepatitis B who failed to respond to alpha-interferon. J Hepatol 2002;37:655-659.
8. Cotonat T, Quiroga JA, Lopez-Alcorocho JM, Clouet R, Pardo M, Manzarbeitia F, et al. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. Hepatology 2000;31:502-506.
9. Mutimer D, Naoumov NV, Honkoop P, Marinos G, Ahmed M, de Man R, et al. Combination alfa-interferon and lamivudine therapy for alfa-interferon resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998; 28:923-929.
10. Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, et al. Lamivudine/interferon combination therapy in anti-HBe-positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002;36:799-804.
11. Jaboli MF, Fabri C, Liva S, Azzaroli F, Nigro G, Giovanelli S, et al. Long-term alfa interferon and lamivudine combination therapy in nonresponder patients with anti-HBepositive chronic hepatitis B: results of an open, controlled trial. World J Gastroenterology 2003;9:1491-1495.
12. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perillo RP, Husa P, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis Be antigen positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-826.
13. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001;34:573-577.
14. Heintges T, Petry W, Kaldewey M, Erhardt A, Wend UC, Gerlich WH, et al. Combination therapy of active HBsAg vaccination and interferon-a nonresponders with chronic hepatitis B. Dig Dis Sci 2001;46:901-906.
15. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
16. Janssen HL, Schalm SW, Berk L, de Man RA, Heijtink RA. Repeated courses of alfa-interferon for treatment of chronic hepatitis B. J Hepatol 1993;17(Suppl 3):S47-S51.
17. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-807.
19. Schiff E, Willems B, Leung N, Lau G, Trepo C, Wright T, et al. Addition of Adefovir dipivoxil to lamivudine therapy results in a significant reduction in HBV DNA and serum ALT in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine-52 week results. Hepatology 2002;36:636A.
20. Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844-1847.
21. Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, et al. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol 2002;37: 922-927.
22. Shiffman ML. Retreatment of HCV nonresponders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2002;36:295A.
23. Gross JB, Kwo P, Afdhal N and RENEW Investigator Group. Mayo clinic, Rochester, MN. Interim results in the RENEW trial: a dose comparison study of high-dose peginterferon alfa-2b and ribavirin for interferon/ ribavirin nonresponders with chronic hepatitis C. Hepatology 2002;36:783A.
24. Lawitz EJ, Bala NS, Becker S, Brown G, Davis M, Dhar R, et al. Pegylated interferon alfa-2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy. Gastroenterology 2003;124(Suppl 1):204.
25. Sulkowski M, Rothstein K, Stein L, Godofsky E, Goodman R, Moorehead L, et al. PEG interferon-a2b t ribavirin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained virological response following interferon a or interferon-a2b t ribavirin therapy. Gastroenterology 2003;124(Suppl 1):204.
26. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigenpositive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
27. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250.
28. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129.
29. Amarapurkar DN, Patel ND Combination of Peginterferon alpha-2b (12 kDa) and Lamivudine in difficult-to-treat chronic hepatitis B an Indian experience. Ann Hepatol 2005;4:56-59.
30. Ishak K, Baptista A, Bianchi L, Callea F, De Groste J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
31. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001;120:1828-1853.